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Whether Cell block (CB) samples are applicable to detect anaplastic lymphoma kinase (ALK), c-ros oncogene 1
(ROS1) and ret proto-oncogene (RET) fusion genes in lung adenocarcinoma is still unknown. In this study, 108
cytological samples that contained lung adenocarcinoma cells were collected, and made into CB. The CB samples
all contained at least 30% lung adenocarcinoma cells. In these patients, 48 harbored EGFR mutation. Among the
50 EGFR wild type patients who detected fusion genes, 14 carried EML4-ALK fusion (28%), 2 had TPM3-ROS1
fusion (4%), and 3 harbored KIF5B-RET fusion (6%). No double fusions were found in one sample. Patients with
fusion genes were younger than those without fusion genes (p = 0.032), but no significant difference was found in
sex and smoking status (p N 0.05). In the thirty-five patients who received first-line chemotherapy, patients with
fusion gene positive had disease control rate (DCR) (72.7% VS 50%, p N 0.05) and objective response rate (ORR)
(9.1% VS 4.2%, p N 0.05) compared with those having fusion gene negative. The median progression free survival
(mPFS) were 4.0 and 2.7 months in patients harbored fusion mutations and wild type, respectively (p N 0.05). We
conclude that CB samples could be used to detect ALK, ROS1 and RET fusions in NSCLC. The frequency
distribution of three fusion genes is higher in lung adenocarcinoma with wild-type EGFR, compared with
unselected NSCLC patient population. Patients with fusion genes positive are younger than those with fusion gene
negative, but they had no significantly different PFS in first-line chemotherapy.
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Lung cancer is the leading cause of cancer death worldwide [1], non–
small-cell lung cancer (NSCLC) accounts for about 85%. Along with the
discovery of somatic epidermal growth factor receptor (EGFR)mutations,
NSCLC patients with activating EGFR mutations benefit from EGFR-
TKI therapy [2–4]. Since then, targeted therapies according to gene
mutations lead a new trend in tumor therapy. Subsequently, more driver
mutations are found in NSCLC, including many fusion gene mutations,
such as anaplastic lymphoma kinase (ALK), ROS1 and RET.
Echinoderm microtubule associated protein like 4 (EML4)-ALK is
the first targetable fusion gene to be identified in NSCLC [5]. The
fusion is found about 2-7% in lung cancer [5–8]. Other genes which
can fuse with ALK had also been found, including KIF5B and TFG
[7,9,10]. In NSCLC never/light smokers without EGFR mutation
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adenocarcinoma patients with malignant pleural effusions having
wild-type EGFR and measurable target lesions it was reported as 34%
[12]. Many drugs that target EML4-ALK had been discovered, such
as crizotinib, which was effective in ALK-rearranged NSCLC [13]
and approved by US food and drug administration (FDA) in treating
ALK-positive NSCLC. ROS1 was also reported to be a target of
crizotinib [14,15], but its frequency only ranges from 0.7-1.7%
[13,15–17] in lung adenocarcinoma. RET, as another fusion gene, is
rarely detected in NSCLC, which is reported from 1-2% [18–20].
Several drugs (sunitinib, sorafenib, and vandetanib) that target RET
fusions are effective [18,21].
Molecular typing is essential for NSCLC patients to select the
optimal treatment. Although tumor tissue is the most valuable
specimen for gene mutation detection, it is not always available
especially for advanced NSCLC patients that are old aged and have
inoperable tumor. In advanced lung cancer patients, 50% has
malignant pleural effusions and 80% of the effusions can find tumor
cells in microscope [22,23]. Therefore, this kind of cytological
samples could be a surrogate to tumor tissues. In this study, CB
samples were done and used to detect ALK, ROS1 and RET fusion
genes, the relationship between clinicopathologic characteristics and
the fusion genes were analyzed.
Method
Patients and CB Samples
108 patients with pleural, ascitic or pericardial effusions conducted
EGFR mutation detection. They were all lung adenocarcinoa patients, in
stage IV and had PS score 0-1. All patients had signed an informed
consent for future molecular analyses. Patient follow-up was ended in
20th, December, 2013. The effusions (50 to 1200 ml) containing lung
adenocarcinoma cells were collected from October 2012 to August 2013.
Simply, the effusion was centrifuged at 2500 rpm for 3 minutes, the
supernatant was removed and the precipitant was mixed with erythrocyte
lysate for 10 minutes. After centrifuging at 2500 rpm for 3 minutes the
precipitant was resuspended in normal saline solution and then was
centrifuged again. The precipitant was packaged by mixing with warm
agarose gel and had routinely dehydration before packaging in paraffinFigure 1. Cell block samples contain lung adenocarcinoma cells. CB
hematoxylin and eosin. The lung adenocarcinoma cells in the picturewax. Sections of 5 μm thick from the samples were used for hematoxylin
and eosin staining and assessed by pathologists.
EGFR Mutations Detection
DNA was extracted from the 108 effusion samples or CB samples
using tissue DNA kit and FFPE DNA kit (QIAGEN, Hilden,
Germany) respectively. EGFR was examined using amplification
refractory mutation system (ARMS) PCR method. The ARMS PCR
procedure was as follows: 5 μl of 1 (effusion samples) or 2 ng/μl (CB
samples) template DNA solutions was added to each reaction buffer
and then [1] initial denaturation at 95°C for 5 min, [2] 15 cycles of
95°C 25 s, 64°C 20s, and 72°C 20s, [3] 31 cycles of 93°C 25 s, 60°C
35 s, and 72°C 20s was conducted before analyzing the results.
ALK, ROS1 and RET Fusion Gene Detection by ARMS PCR
CB samples were scraped into 1.5 mL tubes, and then total RNA
was extracted using RNeasy FFPE kit (QIAGEN, Hilden, Germany).
RNA was reversed to cDNA, added to reaction buffer and then ALK,
ROS1 and RET fusion genes were detected using EML4-ALK, ROS1
and RET Fusion Gene Detection Kit (Amoydx, Xiamen, China)
respectively by ARMS method as mentioned above. All the fusion
positive samples were confirmed by DNA sequencing.
Statistical Analysis
The ORR, DCR, the relationship between fusion gene mutations
and other clinical characteristics were evaluated by Pearson Chi-
square test or Fisher’s exact test. Median PFS was analyzed by
Kaplan–Meier method and compared between different groups using
the log-rank test. The 2-sided significance level was set at P b 0.05. All
data were analyzed using the Statistical Package for the Social Sciences
version 17.0 software package (SPSS Inc., Chicago, Ill).
Results
The Quality of CB Samples
The CB samples were preserved between days to 10 months before
cut into 5 μm thick sections, and then routinely stained by
hematoxylin and eosin. Tumor cell content and pathological type
were assessed by pathologists (Figure 1). All the samples weresamples of 5 μm thick sections from two patients were stained by
s were marked by the black arrows.
Table 1. EGFR Mutation in 108 Lung Adenocarcinoma Patients.
Characteristic Patients Without EGFR Mutation Patients with EGFR Mutation P Value
Age, years
b65 41 38 0.080
≥65 19 10
Sex







Light smokers: smoking less than 10 pack-years.
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each specimen was more than 30%.
ALK, ROS1 and RET Fusion Types in the Fusion
Positive Patients
In the 108 patients, 48 (44%) had EGFR mutation. The
characteristics of the 108 lung adenocarcinoma patients were listed
in Table 1. They had no significant difference in age, sex and smoking
status between patients with or without EGFR mutation. In the
EGFR wild type patients 50 conducted fusion gene detection. Of
these, 14 had ALK fusion (28%), 2 had ROS1 fusion (4%), and 3 had
RET fusion (6%). PCR positive samples were all verified by DNA
sequencing. The ALK fusions were: eight E(EML4) exon 13 with A
(ALK) exon 20 fusions, four E20 with A20 fusions, one E18 with
A20 fusion, and one E6 with A20 fusion. The ROS1 fusions were
ROS1 exon 34 with TPM3 exon 8. The three RET fusions were all
RET exon 12 with KIF5B exon n15.
Clinicopathologic Characteristics of the Gene Fusion
Positive Patients
The patients who harbored fusion gene mutation were listed in
Table 2. In the EML4-ALK patients, 11 were under 60 and 8 were
none or light smokers. The TPM3-ROS1 and two KIF5B-RET
patients were under 60 years old and none-smokers, and one KIF5B-
RET patient was a heavy smoker (30 pack-years) and under 60. There
was no significant difference between the patients with and without
any one of the fusion genes in sex, and smoking status (p N 0.05), but
the patients with fusion gene mutations were younger than those
without mutations (median age, 51 vs 61, p = 0.032).
Clinical Outcome of PatientsWith andWithout the Fusion Genes
Thirty-five of the 50 patients received first-line chemotherapy in
this hospital, including 29 carboplatin or cisplatin contained



















b65 11 2 3 16 17 0.032
≥65 3 0 0 3 14
Sex
Male 9 1 1 11 18 0.610
Female 5 1 2 8 13
Smoking status
Never/light smoker 8 2 2 12 16 0.308
Smoker 6 0 1 7 15
Table 3. Response to First-line Chemotherapy in Lung Adenocarcinoma Patients (n = 35).
Response ALK Positive
Patients (n = 8)
Ros1 Positive
Patients (n = 0)
RET Positive
Patients (n = 3)
Gene Wild Type
Patients (n = 24
PR 0 0 1 1
SD 6 0 1 11therapies. In these patients, twenty-four did not carry any mutation of
three fusion genes, eight were ALK fusion positive and three were
RET fusion positive (Table 3). In the last follow-up, three patients
did not get disease progression. ORR was 4.2% and 9.1% in patients
without and with fusion gene mutation, respectively (p N 0.05); DCR
was 50% and 72.7%, respectively (p N 0.05). The median PFS of the
EML4-ALK positive patients was 4.2 (95% confidence interals,
1.890-6.510) months vs 2.8 (95% CI, 1.658-3.942) months (p =
0.706) in the EML4-ALK negative patients and in either one of three
genes positive patients it was 4.0 (95% CI, 2.605-5.395) months vs
2.7 (95% CI, 1.551-3.849) months (p = 0.371) in the none-positive
patients (Figure 2). Although there was no significant difference
between the two cohorts, the results showed a trend that patients with
fusion genes had a better chemotherapy response than those without
any one of fusion genes in chemotherapy.
Discussion
Cell block (CB) is a method to concentrate and preserve cells in fluid
samples for long use. Compared with effusion smears, CB contains
more cells to be identified and helps pathologists in decision making.
It has been used routinely in pathological classification and also in
gene detection. In certain cases it has an advantage to other
conventional pathological methods [24]. In advanced-stage patients
who cannot have their tissues dissected, CB samples could be an
alternative selection. In this study, the authors detected ALK, ROS1
and RET fusion genes in EGFR wild type lung adenocarcinoma
patients using cell block samples and analyzed the prevalence of the
fusion genes and the relationship between clinicopathologic charac-
teristics and fusion gene mutations.
Fluorescence in situ hybridization (FISH) is the primary method to
detect ALK, ROS1 and RET fusions in NSCLC [14,25,26].
However, it is not wildly used in China due to its high spent, time
consuming and also the interpretation of results. Immunohistochem-
istry (IHC) is another method to detect ALK fusion, but there is no
standard procedure for all the labs and the same result could be
explained differently by different pathologists. Soda showed us in his
study that different technologies should apply to different samples,
and multiplex RT-PCR was applicable for the fluid samples [27].
Here, we use a reverse-transcript polymerase chain reaction (RT-
PCR) method-ARMS-to detect ALK, ROS1 and RET fusions in 50
CB samples. Wu [12] used RT-PCR and FISH to detect ALK fusion
and they found a concordance rate of 85%, but they did not check
cell block samples that were ALK fusion positive using FISH. Soda
[27] reported in their research that PCR-based detection of EML4-
ALK should have a higher analytic sensitivity compared with IHC or
FISH. In this study, although we did not use FISH to conform the
PCR results, we used DNA sequencing as a substitute. All the positive
results using the PCR method were all conformed by DNA
sequencing. We believe that the cell block samples could detect the
three fusion genes using both RT-PCR and DNA sequencing.
We tested the quality of cell block samples from the points of
malignant cell ratio and PCR controls, finding that they werePD 2 0 1 12)
Figure 2. Comparison of PFS betweenpatientswith orwithout fusion genes. The change of PFSbetween patientswith orwithout EML4-ALK
mutation (left) and the change of PFS between patients with or without any fusion gene mutation (right) were shown in the figure.
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validated by DNA sequencing and the specific variants were also
given. The results indicate that cell block samples preserved at least 10
months could be used to detect fusion genes. EML4-ALK fusion gene
detection using plural effusions had been reported by Wu et al [12].
They used RT-PCR and direct sequencing methods and found a 34%
presence in EGFR wild type lung adenocarcinoma patients. Shaw et
al. [19] got a 33% prevalence in never/light smokers in EGFR wild
type lung adenocarcinoma patients using FISH method. Although
Cai et.al [28] used 19 cell block samples and 35 fine-needle aspirates
to detect EGFR, KRAS and ALK genes in primary and metastatic
lung adenocarcinomas, they did not show whether the CB samples be
used for ALK detection or not. As far as we know, there is no study
that reports the three fusion genes detected specially using CB
samples. In the 50 EGFR wild type lung adenocarcinoma patients,
EML4-ALK had a prevalence of 28%, which was a little lower than
the former data [11,12]. Nonetheless, considering the small number
of cases in our study, this slight difference should be reasonable. We
had also examined ROS1 and RET fusion genes in the 50 samples.
Compared with their frequency in NSCLC or lung adenocarcinoma
(1-2%), they were 2-3 times higher in EGFR wild type lung
adenocarcinoma. Therefore, gene screening on the basis of other
genes may improve its detection rate.
No significant difference was found between patients with and
without genes mutation in sex and smoking status (p N 0.05), but
they as a whole had a significant difference in age (51 versus 61, p =
0.032). The patients with fusion genes are younger than those
without mutations, which is in concordance with other reports
[11,18,29,30]. In the absence of EML4-ALK targeted therapy,
patients have a similar prognosis whether ALK was fusion positive or
not [7], but other data indicate that the prognosis is controversial
[12,31]. Here, we observed that patients with fusion genes had a
clinical benefit in ORR, DCR and median PFS than those without
mutations. Although they were not significantly different, which
may due to the limitation of the sample numbers, the results showed
a positive response in the patients harboring fusion genes. In
addition, the new targeted medicines for ALK, ROS1 and RET have
been come into the market or in clinical trials. For example,
crizotinib was approved by US FDA in 2011 for the treatment of
patients with locally advanced or metastatic ALK-positive NSCLC
and it was available in the market of China since June 2013.Sunitinib, sorafenib and vandetanib could effectively inhibit RET
positive lung cancer cells [21].
In this study, we demonstrated that CB samples could be an option
to substitute tissues to detect ALK, ROS1 and RET fusion genes in
lung cancer patients. Patients with fusion gene mutation may have a
better clinical response than those without mutations, which needed
to be confirmed by a large sample study.
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